Exhibit 99.1 Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update Achieved first-ever RNA editing in humans in RestorAATion-2 trial of WVE-006 (GalNAc-AIMer) in alpha-1 antitrypsin deficiency and announced three wholly owned GalNAc-AIMer preclinical programs that of er first-in-class approaches to address unmet needs in cardiometabolic diseases WVE-007 (INHBE GalNAc-siRNA) clinical trial on track for 1Q 2025; preclinical data demonstrates opportunities for monotherapy ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Wave Life Sciences (WVE) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Novem ...

Wave Life Sciences (WVE) closed the last trading session at $14.45, gaining 74.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $19.44 indicates a 34.5% upside potential. The mean estimate comprises nine short-term price targets with a standard deviation of $2.70. While the lowest estimate of $15 indicates a 3.8% increase from the current price level, the most optimistic analyst ...

This stock currently has a good balance of risk and potential rewards.With its shares skyrocketing by upwards of 74% on Oct. 16, Wave Life Sciences (WVE -1.08%) is now on the map of many investors. Per an update from one of its early-stage clinical trials, it just marked a first-in-humans scientific milestone. That cleared the way for its stock to continue gaining value as the biotech builds on its preliminary results.So what exactly did this company accomplish, and how important is it going to be in the lo ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

Wave Life Sciences Today WVE Wave Life Sciences $14.61 -0.29 (-1.95%) 52-Week Range $3.50 ▼ $15.92 Price Target $18.56 Add to Watchlist Wave Life Sciences Ltd. NASDAQ: WVE is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. The company is generating significant interest from investors due to its dedication to RNA editing, a novel approach to treating a range of genetic diseases. Wave Life Sciences is one of the pioneers in this bioph ...

Shares of Wave Life Sciences (WVE) surged 74.1% on Wednesday after the company reported positive proofof-mechanism data from an ongoing early to mid-stage study of its investigational candidate, WVE-006, for alpha-1 antitrypsin deficiency (AATD), a type of genetic disorder. WVE-006 is a GalNAc-conjugated oligonucleotide that enables A-to-I RNA editing and is administered subcutaneously. Developed with Wave Life Sciences' advanced oligonucleotide chemistry platform, it is specifically designed to target lung ...

Wave Life Sciences (WVE) shares rallied 74.1% in the last trading session to close at $14.90. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 49.9% gain over the past four weeks. The sudden rise in the stock price was observed after the company announced positive proof-of-mechanism data, showing first-ever therapeutic RNA editing in humans, from the first single-dose cohort (200 mg) of the phase Ib/IIa Restor ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

CAMBRIDGE, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced it will host a virtual Research Day on Wednesday, October 30, 2024 at 10:00 a.m. ET (until 11:30 a.m. ET). During the event, Wave will provide an update on its rapidly advancing, wholly owned pipeline, introduce new GalNAc-conjugated RNA editing and siRNA programs, and discuss its ...